{"id":"NCT03425539","sponsor":"Idorsia Pharmaceuticals Ltd.","briefTitle":"Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease","officialTitle":"A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-21","primaryCompletion":"2021-08-17","completion":"2021-09-02","firstPosted":"2018-02-07","resultsPosted":"2024-08-09","lastUpdate":"2024-08-09"},"enrollment":118,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"DRUG","name":"Lucerastat","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lucerastat","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.","primaryOutcome":{"measure":"Neuropathic Pain Monthly Score: Change From Baseline to Month 6","timeFrame":"From baseline to Month 6 (duration: 6 months)","effectByArm":[{"arm":"Lucerastat","deltaMin":-1.64,"sd":null},{"arm":"Placebo","deltaMin":-2.05,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3189"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":49,"countries":["United States","Australia","Austria","Belgium","Canada","Germany","Ireland","Italy","Netherlands","Norway","Poland","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":80},"commonTop":["Nasopharyngitis","Headache","Nausea","Diarrhoea","Fatigue"]}}